ArticleJTO clinical and research reports2025

CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB-IIIA NSCLC.

Jay M Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.